2021
DOI: 10.1136/bmjgh-2020-004750
|View full text |Cite
|
Sign up to set email alerts
|

Unseen and unheard: African children with cancer are consistently excluded from clinical trials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 12 publications
0
2
0
Order By: Relevance
“…The incidence of childhood cancer varies significantly between regions, with approximately 90% of the cases being from low‐ and middle‐income countries (LMICs), where 95% of children of this age live 1 . In Africa, cancer incidence is particularly high, with an estimated 100,000 new cases annually under the age of 15 years and the incidence is expected to double by 2030 2,3 . Malawi, like other LMICs in sub‐Saharan Africa, has a high childhood cancer burden, with 1108 cases reported in 2020 4 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The incidence of childhood cancer varies significantly between regions, with approximately 90% of the cases being from low‐ and middle‐income countries (LMICs), where 95% of children of this age live 1 . In Africa, cancer incidence is particularly high, with an estimated 100,000 new cases annually under the age of 15 years and the incidence is expected to double by 2030 2,3 . Malawi, like other LMICs in sub‐Saharan Africa, has a high childhood cancer burden, with 1108 cases reported in 2020 4 .…”
Section: Introductionmentioning
confidence: 99%
“…1 In Africa, cancer incidence is particularly high, with an estimated 100,000 new cases annually under the age of 15 years and the incidence is expected to double by 2030. 2 , 3 Malawi, like other LMICs in sub‐Saharan Africa, has a high childhood cancer burden, with 1108 cases reported in 2020. 4 Acute lymphoblastic leukaemia is the most common childhood cancer globally, followed by non‐Hodgkin lymphoma, nephroblastoma, Burkitt lymphoma and Retinoblastoma.…”
Section: Introductionmentioning
confidence: 99%